CAMP4 Therapeutics Corp (CAMP)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.30-2.65%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge CAMP4 Therapeutics Corp’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1.93M
EPS	—	-0.192
Annual ending 2026-12-31
Revenue	—	6.37M
EPS	—	-1.136
Annual ending 2027-12-31
Revenue	—	5.64M
EPS	—	-0.782

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS loss narrows toward -$0.79 in 2026	A primary condition in CAMP4 Therapeutics Corp's published investment case. The stated target is EPS >= -0.79 USD per share.	Broken	EPS loss worsens beyond -0.79 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth of about 45% in 2026	A primary condition in CAMP4 Therapeutics Corp's published investment case. The stated target is >=44.9% YoY.	Intact	YoY revenue growth falls below 44.9% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful collaboration with GSK and new board members	The company added a new board member.	Intact	Loss of key partnerships or leadership changes hurt growth	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.78

$-0.73 → $-0.78 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.73	$5,842,857	5 / 5
2026-07-25	$-0.73	$5,842,857	5 / 5
2026-07-26	$-0.73	$5,842,857	5 / 5
2026-07-27	$-0.73	$5,842,857	5 / 5
2026-07-28	$-0.73	$5,842,857	5 / 5
2026-07-29	$-0.73	$5,842,857	5 / 5
2026-07-30	Unavailable	$6,816,670	4 / 6
2026-07-31	Unavailable	$6,816,670	4 / 6
2026-08-01	Unavailable	$6,816,670	4 / 6
2026-08-02	Unavailable	$6,816,670	4 / 6
2026-08-03	Unavailable	$6,816,670	4 / 6
2026-08-04	$-0.73	$5,842,857	5 / 5
2026-08-05	Unavailable	$6,816,670	4 / 6
2026-08-06	Unavailable	$6,816,670	4 / 6
2026-08-07	$-0.73	$5,842,857	5 / 5
2026-08-08	$-0.73	$5,842,857	5 / 5
2026-08-09	Unavailable	$6,816,670	4 / 6
2026-08-10	$-0.73	$5,842,857	5 / 5
2026-08-11	$-0.73	$5,842,857	5 / 5
2026-08-12	Unavailable	$6,816,670	4 / 6
2026-08-13	$-0.73	$5,842,857	5 / 5
2026-08-14	$-0.73	$5,842,857	5 / 5
2026-08-15	$-0.73	$5,842,857	5 / 5
2026-08-16	$-0.73	$5,842,857	5 / 5
2026-08-17	$-0.73	$5,842,857	5 / 5
2026-08-18	$-0.73	$5,842,857	5 / 5
2026-08-19	$-0.73	$5,842,857	5 / 5
2026-08-20	$-0.73	$5,204,429	5 / 5
2026-08-21	$-0.73	$5,204,429	5 / 5
2026-08-22	$-0.73	$5,204,429	5 / 5
2026-08-23	$-0.73	$5,204,429	5 / 5
2026-08-24	$-0.73	$5,204,429	5 / 5
2026-08-25	$-0.73	$5,204,429	5 / 5
2026-08-26	$-0.73	$5,204,429	5 / 5
2026-08-27	$-0.73	$5,204,429	5 / 5
2026-08-28	$-0.73	$5,204,429	5 / 5
2026-08-29	$-0.73	$5,204,429	5 / 5
2026-08-30	$-0.73	$5,204,429	5 / 5
2026-08-31	$-0.73	$5,204,429	5 / 5
2026-09-01	$-0.73	$5,204,429	5 / 5
2026-09-02	$-0.73	$5,204,429	5 / 5
2026-09-03	$-0.73	$5,204,429	5 / 5
2026-09-04	$-0.73	$5,204,429	5 / 5
2026-09-05	$-0.73	$5,204,429	5 / 5
2026-09-06	$-0.73	$5,204,429	5 / 5
2026-09-07	$-0.73	$5,204,429	5 / 5
2026-09-08	$-0.73	$5,204,429	5 / 5
2026-09-09	$-0.73	$5,204,429	5 / 5
2026-09-10	$-0.73	$5,204,429	5 / 5
2026-09-11	$-0.73	$5,204,429	5 / 5
2026-09-12	$-0.73	$5,204,429	5 / 5
2026-09-13	$-0.73	$5,204,429	5 / 5
2026-09-14	$-0.73	$5,204,429	5 / 5
2026-09-15	$-0.73	$5,204,429	5 / 5
2026-09-16	$-0.73	$5,204,429	5 / 5
2026-09-17	$-0.73	$5,204,429	5 / 5
2026-09-18	$-0.73	$5,204,429	5 / 5
2026-09-19	$-0.73	$5,204,429	5 / 5
2026-09-20	$-0.73	$5,204,429	5 / 5
2026-09-21	$-0.73	$5,204,429	5 / 5
2026-09-22	$-0.73	$5,204,429	5 / 5
2026-09-23	$-0.73	$5,204,429	5 / 5
2026-09-24	$-0.73	$6,071,833	5 / 5
2026-09-25	$-0.73	$6,071,833	5 / 5
2026-09-26	$-0.73	$6,071,833	5 / 5
2026-09-27	$-0.73	$6,071,833	5 / 5
2026-09-28	$-0.73	$6,071,833	5 / 5
2026-09-29	$-0.73	$6,071,833	5 / 5
2026-09-30	$-0.73	$6,083,333	5 / 5
2026-10-01	$-0.73	$6,083,333	5 / 5
2026-10-02	$-0.73	$6,083,333	5 / 5
2026-10-03	$-0.73	$6,083,333	5 / 5
2026-10-04	$-0.73	$6,083,333	5 / 5
2026-10-05	$-0.73	$6,083,333	5 / 5
2026-10-06	$-0.75	$5,642,857	5 / 5
2026-10-07	$-0.75	$5,642,857	6 / 5
2026-10-08	$-0.75	$5,642,857	6 / 6
2026-10-09	$-0.75	$5,642,857	6 / 6
2026-10-10	$-0.75	$5,642,857	6 / 6
2026-10-11	$-0.75	$5,642,857	6 / 6
2026-10-12	$-0.75	$5,642,857	6 / 6
2026-10-13	$-0.75	$5,642,857	6 / 6
2026-10-14	$-0.75	$5,642,857	6 / 6
2026-10-15	$-0.75	$5,642,857	6 / 6
2026-10-16	$-0.75	$5,642,857	6 / 6
2026-10-17	$-0.75	$5,642,857	6 / 6
2026-10-18	$-0.78	$5,642,857	7 / 6
2026-10-19	$-0.78	$5,642,857	7 / 6
2026-10-20	$-0.78	$5,642,857	7 / 6
2026-10-21	$-0.78	$5,642,857	7 / 6
2026-10-22	$-0.78	$5,642,857	7 / 6
2026-10-23	$-0.78	$5,642,857	7 / 6
2026-10-24	$-0.78	$5,642,857	7 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	5	1
2026-06-01	7	1
2026-07-01	7	0
2026-08-01	7	0
2026-09-01	7	0
2026-10-01	10	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Raymond JamesOct 23

$10.00New observation · no comparable prior

NeedhamOct 15

$8.00New observation · no comparable prior

Chardan CapitalSep 29 · prior Jun 10

$6.50 → $6.00-7.7%

$0$5.50$11.00

0 raises · 1 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS loss narrows toward -$0.79 in 2026Published status: Broken
Revenue growth of about 45% in 2026Direct metric needs a verified mapping
Successful collaboration with GSK and new board membersQualitative condition

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.1%Typical daily move · historical

Downside history

-57.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

CAMP4 Therapeutics Corp outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotech, where the long-term thesis depends on research progress rather than established profits. The thesis is in a watch state: management is on track to start a Phase 1/2 trial, but recent performance trails its industry cohort and risk remains high.

What's priced into CAMP4 Therapeutics Corp

The valuation model shows a 3.9 premium versus peers, while its low-confidence expectations-gap measure is negative and identifies optionality as the main source of valuation divergence. The evidence labels pricing as justified with low fragility, but does not establish that expectations are easy to meet.

What the fundamentals likely do

Near term, CAMP remains loss-making, and a 44% estimated miss probability warrants attention at the next report. An August earnings beat is a positive data point, while cash was $86.4 million in the second quarter after a $50.1 million private placement; management says financing supports a runway into 2028, though cash declined from the prior quarter. For the multi-year view, trial initiation is anticipated in the second half of 2026, backed by regulatory clearance in Australia and Argentina and preclinical mouse-model data.

What CAMP4 Therapeutics Corp hinges on

The key clinical swing factor is whether CAMP starts the CMP-002 Phase 1/2 trial on its stated timeline and advances the program with evidence that supports its potential. A guidance cut or further weakening in jobs data could add pressure, while strength among healthcare bellwethers may support the sector backdrop. Continued cash availability also matters as the company advances research.